Rexlemestrocel-L

Drug Profile

Rexlemestrocel-L

Alternative Names: Allogeneic mesenchymal precursor cells - Mesoblast; CEP-41750; Mesenchymal stem cell therapy - Mesoblast; MPC 06; MPC-06-ID; MPC-150; MPC-150-IM; MPC-25; MPC-25-IC; MPC-300; MPC-300-IV; MPC-75-IA; MPC-CBE; MPC-MICRO-IO; MSB-CAR001; NeoFuse; Replicart; Revascor

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Hanson Institute; Institute of Medical and Veterinary Science
  • Developer Angioblast Systems; Mesoblast; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antihypercalcaemics; Antineoplastics; Antirheumatics; Heart failure therapies; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Heart failure; Intervertebral disc degeneration; Non-Hodgkin's lymphoma
  • Phase II Myocardial infarction; Osteoarthritis; Rheumatoid arthritis; Spondylosis; Type 2 diabetes mellitus
  • Phase I/II Diabetic nephropathies
  • Preclinical Age-related macular degeneration; Lung disorders
  • No development reported Fracture; Peripheral arterial disorders; Skin ulcer

Most Recent Events

  • 23 Dec 2016 Mesoblast and Mallinckrodt Pharmaceuticals enter into an agreeement for the development and commercialisation of Rexlemestrocel-L, worldwide excluding Japan and China for Intervertebral disc degeneration
  • 06 Dec 2016 MD Anderson Cancer Center and NIH (USA) plan a clinical trial for Cancer (In patients undergoing cord blood transplantation) in USA
  • 25 Aug 2016 Mesoblast completes enrolment in its phase II trial myocardial Infarction in the UK, the Netherlands, Belgium, Denmark, Sweden, Czech Republic, Austria, Poland, Australia and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top